Kathryn S Torok1, Katherine Kurzinski2, Christina Kelsey2, Jonathan Yabes3, Kelsey Magee2, Abbe N Vallejo4, Thomas Medsger5, Carol A Feghali-Bostwick6. 1. Division of Pediatric Rheumatology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA 15224; Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA. Electronic address: kathryn.torok@chp.edu. 2. Division of Pediatric Rheumatology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA 15224. 3. Department of Medicine, University of Pittsburgh, Pittsburgh, PA; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA. 4. Division of Pediatric Rheumatology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA 15224; Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA. 5. Department of Medicine, University of Pittsburgh, Pittsburgh, PA; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA. 6. Department of Medicine, University of Pittsburgh, Pittsburgh, PA; Department of Medicine, Medical University of South Carolina, Charleston, SC.
Abstract
OBJECTIVE: To evaluate peripheral blood T-helper (TH) cell-associated cytokine and chemokine profiles in localized scleroderma (LS), and correlate them with clinical disease features, including disease activity parameters. METHODS: A 29-plex Luminex platform was used to analyze the humoral profile of plasma samples from 69 pediatric LS patients and 71 healthy pediatric controls. Cytokine/chemokine levels were compared between these two groups and within LS patients, focusing on validated clinical outcome measures of disease activity and damage in LS. RESULTS: Plasma levels of IP-10, MCP-1, IL-17a, IL-12p70, GM-CSF, PDGF-bb, IFN-α2, and IFN-γ were significantly higher in LS subjects compared to healthy controls. Analysis within the LS group demonstrated IP-10, TNF-α, and GM-CSF correlated with clinical measures of disease activity. Several cytokines/chemokines correlated with anti-histone antibody, while only a few correlated with positive ANA and single-stranded DNA antibody. CONCLUSION: This is the first time that multiple cytokines and chemokines have been examined simultaneously in LS. In general, a TH1 (IFN-γ) and TH17 (IL-17a) predominance was demonstrated in LS compared to healthy controls. There is also an IFN-γ signature with elevated IP-10, MCP-1, and IFN-γ, which has been previously demonstrated in systemic sclerosis, suggesting a shared pathophysiology. Within the LS patients, those with active disease demonstrated IP-10, TNF-α, and GM-CSF, which may potentially serve as biomarkers of disease activity in the clinical setting.
OBJECTIVE: To evaluate peripheral blood T-helper (TH) cell-associated cytokine and chemokine profiles in localized scleroderma (LS), and correlate them with clinical disease features, including disease activity parameters. METHODS: A 29-plex Luminex platform was used to analyze the humoral profile of plasma samples from 69 pediatric LS patients and 71 healthy pediatric controls. Cytokine/chemokine levels were compared between these two groups and within LS patients, focusing on validated clinical outcome measures of disease activity and damage in LS. RESULTS: Plasma levels of IP-10, MCP-1, IL-17a, IL-12p70, GM-CSF, PDGF-bb, IFN-α2, and IFN-γ were significantly higher in LS subjects compared to healthy controls. Analysis within the LS group demonstrated IP-10, TNF-α, and GM-CSF correlated with clinical measures of disease activity. Several cytokines/chemokines correlated with anti-histone antibody, while only a few correlated with positive ANA and single-stranded DNA antibody. CONCLUSION: This is the first time that multiple cytokines and chemokines have been examined simultaneously in LS. In general, a TH1 (IFN-γ) and TH17 (IL-17a) predominance was demonstrated in LS compared to healthy controls. There is also an IFN-γ signature with elevated IP-10, MCP-1, and IFN-γ, which has been previously demonstrated in systemic sclerosis, suggesting a shared pathophysiology. Within the LS patients, those with active disease demonstrated IP-10, TNF-α, and GM-CSF, which may potentially serve as biomarkers of disease activity in the clinical setting.
Authors: F Zulian; B H Athreya; R Laxer; A M Nelson; S K Feitosa de Oliveira; M G Punaro; R Cuttica; G C Higgins; L W A Van Suijlekom-Smit; T L Moore; C Lindsley; J Garcia-Consuegra; M O Esteves Hilário; L Lepore; C A Silva; C Machado; S M Garay; Y Uziel; G Martini; I Foeldvari; A Peserico; P Woo; J Harper Journal: Rheumatology (Oxford) Date: 2005-12-20 Impact factor: 7.580
Authors: Jorre S Mertens; Marieke M B Seyger; Rogier M Thurlings; Timothy R D J Radstake; Elke M G J de Jong Journal: Am J Clin Dermatol Date: 2017-08 Impact factor: 7.403
Authors: Ian D Ferguson; Patricia Griffin; Joshua J Michel; Hiroshi Yano; Sarah L Gaffen; Robert G Mueller; Jeffrey A Dvergsten; Jon D Piganelli; Margalit E Rosenkranz; Daniel A Kietz; Abbe N Vallejo Journal: Front Immunol Date: 2018-08-06 Impact factor: 7.561